Natera Inc Stock Price, News & Analysis

Natera (NASDAQ: NTRA), a leader in cell-free DNA and genetic testing, has announced its participation in three major healthcare investor conferences. The company will present at the UBS Global Healthcare Conference on November 14, the Wolfe Research Healthcare Conference on November 19, and the 36th Annual Piper Sandler Healthcare Conference on December 3. All presentations will be accessible via live webcast through Natera's investor relations website, with replays available after each event.

Natera, a global leader in cell-free DNA and genetic testing, has announced it will release its third quarter 2024 financial results on November 12, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day. Investors can access the call through domestic (1-888-770-7321) or international (1-929-201-7107) dial-in numbers using conference ID 7684785.

Natera (NASDAQ: NTRA) will present new data on its 385-gene kidney genetic test, Renasight™, at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego from Oct. 23-27. The company and collaborators will present 7 abstracts focused on comprehensive genetic testing for patients with chronic kidney disease (CKD).

This includes an updated analysis from the prospective RenaCARE study and additional data on the utility of genetic testing for CKD patients. The presentations align with recent support for renal genetic testing from organizations like NKF, KDIGO, and The New England Journal of Medicine.

Dr. Anthony Bleyer of Wake Forest University School of Medicine highlighted that 25% of dialysis patients don't know their kidney disease cause, emphasizing the importance of genetic testing. Natera's presentations will cover topics such as patient satisfaction with genetic counseling, genetic testing results in African American patients, and the genetic landscape of glomerular disease and FSGS.

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has provided an update on its patent infringement litigation against NeoGenomics. On September 23, 2024, the District Court for the Middle District of North Carolina issued a permanent injunction against NeoGenomics' accused RaDaR assay, following a preliminary injunction from December 2023.

Natera is continuing to pursue its claim against a modified version of RaDaR for infringement of Natera's '454 patent. The company is seeking full remedies, including injunctive relief, especially after the Patent Office denied NeoGenomics' petition for 'inter partes' review challenging the validity of the '454 patent.

Natera (NASDAQ: NTRA) announced three new peer-reviewed publications for its Signatera test, surpassing 85 total publications. Key highlights include:

1. Colorectal cancer (CRC) data from the GALAXY arm of CIRCULATE-Japan, published in Nature Medicine and presented at ESMO 2024, showing Signatera's ability to predict overall survival and adjuvant chemotherapy benefit.

2. Additional CRC data from GALAXY, published in Annals of Oncology, demonstrating Signatera's ability to risk-stratify patients after liver metastases resection.

3. Breast cancer data from the BELLINI trial, published in Nature Medicine, exploring immune checkpoint inhibitors without chemotherapy in triple-negative breast cancer, with Signatera showing correlation to treatment response.

Natera, Inc. (NASDAQ: NTRA) announced new data from the GALAXY arm of the CIRCULATE-Japan trial at the 2024 ESMO Congress. The study, involving 2,240 patients with stage II-IV colorectal cancer, demonstrated Signatera's ability to predict overall survival (OS) and adjuvant chemotherapy (ACT) benefit. Key findings include:

1. Signatera-positive patients showed 9.68 times higher risk of death compared to Signatera-negative patients.

2. Signatera-positive patients receiving ACT had a 50% reduction in death risk.

3. Signatera status was the most significant predictor of recurrence across all pathologic stages.

4. Sustained Signatera clearance after ACT was associated with 100% 24-month OS.

These results highlight Signatera's potential to improve outcomes for colorectal cancer patients through personalized treatment decisions.

Natera will present new data on its Signatera molecular residual disease (MRD) test at the 2024 ESMO Congress. Key highlights include:

1. Data from the GALAXY arm of CIRCULATE-Japan trial, showing Signatera-positive patients had significantly shorter overall survival (OS) compared to Signatera-negative patients (hazard ratio ~10).

2. First prospective read-out of OS based on MRD in colorectal cancer (CRC).

3. New data on adjuvant chemotherapy (ACT) benefit in Signatera-positive and negative patients.

4. Additional presentations on Signatera in breast cancer and squamous cell carcinoma of the head and neck.

These findings underscore Signatera's potential to predict long-term outcomes and guide treatment decisions in early-stage CRC.

Natera, a leader in cell-free DNA and genetic testing, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Wednesday, Sept. 4 at 2:35 pm ET | 11:35 am PT in New York City. Natera's leadership team will be presenting at the conference.

Investors and interested parties can access a live webcast and audio archive of the presentation through the investor relations section of Natera's website at investor.natera.com. A replay of the event will be made available shortly after the conference concludes.

This participation highlights Natera's commitment to engaging with the investment community and showcasing its advancements in the field of genetic testing.

Natera (NASDAQ: NTRA), a leader in cell-free DNA and genetic testing, reported its Q2 2024 financial results.

Key highlights include total revenues of $413.4M, up 58.1% YoY, and product revenues of $411.4M, up 59.3%. Gross margin improved to 58.8% from 45.2%. The company processed approximately 760,300 tests, a 23.2% increase, including 125,400 oncology tests, a 50.2% increase. Natera achieved a positive cash flow of $3.3M.

Operating expenses rose to $287.1M, driven by headcount growth and increased consulting and legal costs. Net loss narrowed to $37.5M ($0.30/share) from $110.8M ($0.97/share) YoY. Natera's financial outlook for 2024 expects revenues between $1.49B and $1.52B, with a gross margin of 54%-56%.

The company launched a new feature for ProsperaTM Heart and presented new data at the ASCO 2024 Annual Meeting.